🟢 Tenax Therapeutics is trading 9.4% up in pre-market after subgroup showed 26.3-meter walking improvement

Tenax Therapeutics is trading 9.4% up now at $2.33 after additional Phase 3 LEVEL results were presented at the European Society of Cardiology Congress on August 29, 2026.

• The trial missed its primary endpoint overall.
• A prespecified subgroup showed a 26.3-meter improvement in walking distance, alongside reductions in NT-proBNP and RVSP.
• The company said the findings support enriching its follow-up LEVEL-2 study.